GLP-1 receptor agonists have changed the conversation around weight management more dramatically than any class of medication in decades. Tirzepatide and semaglutide, the active compounds behind Mounjaro, Zepbound, Ozempic, and Wegovy, produce weight loss outcomes once achievable only through bariatric surgery. Clinical trials have shown total body weight reductions of 15 to 22 percent, and for millions of people living with obesity or metabolic disease, that is genuinely lif